To align its production network with its strategy and new technologies, Novartis unveiled planned investments with a focus on Austria. To Novartis’ production capacities with these projects, two new cell culture facilities are being built at the long-standing Tyrolean locations in Kundl and Schaftenau. €250 million will be invested in a facility in Kundl, which is scheduled to be completed by 2025 and will create 180 jobs in the areas of production, quality, and support. In Schaftenau, the alrea...